Skip to main content

Peptic Ulcer

2
Pipeline Programs
3
Companies
3
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Onconic Therapeutics
1 program
1
JP-1366 10 mgPhase 31 trial
Active Trials
NCT06439563Recruiting364Est. Dec 2027
AbbVie
AbbVieNORTH CHICAGO, IL
1 program
1
AGN 201904Phase 11 trial
Active Trials
NCT00325715Completed150Est. Aug 2006
UCB Pharma
UCB PharmaBelgium - Brussels
1 program
Somatostatin UCBPHASE_21 trial
Active Trials
NCT00152399Completed370Est. Oct 2005

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Onconic TherapeuticsJP-1366 10 mg
UCB PharmaSomatostatin UCB
AbbVieAGN 201904

Clinical Trials (3)

Total enrollment: 884 patients across 3 trials

NCT06439563Onconic TherapeuticsJP-1366 10 mg

Study to Evaluate the Efficacy and Safety of JP-1366 in the Prevention of NSAIDs-Induced Peptic Ulcers

Start: Oct 2024Est. completion: Dec 2027364 patients
Phase 3Recruiting
NCT00152399UCB PharmaSomatostatin UCB

Study to Assess the Efficacy and Safety of Somatostatin in the Treatment of Acute Severe Upper Gastrointestinal Bleeding

Start: Sep 2000Est. completion: Oct 2005370 patients
Phase 2Completed
NCT00325715AbbVieAGN 201904

AGN 201904 Versus Esomeprazole in the Prevention of Aspirin-induced Stomach or Upper Intestinal Damage in Healthy Volunteers

Start: Apr 2006Est. completion: Aug 2006150 patients
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 884 patients
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.